KALV Live signals | Maximize Profits with Getagraph.com

BUY 101840 min ago

@ $14.93

Issued: 14 Feb 2024 @ 14:24

Return: -30.65%

Previous signal: Feb 14 - 12:07

Previous signal: Sell

Return: -1.62 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs...

Stats
Today's Volume	418 076
Average Volume	822 880
Market Cap	436.65M
EPS	$0 ( 2024-03-14 )
Next earnings date	( $-0.690 ) 2024-07-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.32
ATR14	$0.0200 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Fairey William	Buy	17 000	Stock Option (Right to Buy)
2024-04-18	Fairey William	Buy	0
2024-03-06	Palleiko Benjamin L	Buy	250 000	Restricted Stock Unit
2024-02-20	Venrock Healthcare Capital Partners Iii, L.p.	Buy	655 738	Pre-Funded Warrants (Right to Buy)
2024-02-17	Feener Edward P.	Buy	18 788	Common Stock

INSIDER POWER
66.06
Last 98 transactions
Buy: 3 056 025 \| Sell: 628 012

Volume Correlation

Long: -0.40 (neutral)

Short: -0.89 (strong negative)

Signal:(37.046) Neutral

Kalvista Pharmaceuticals Correlation

10 Most Positive Correlations
ACLS	0.953
BWMN	0.951
NVCN	0.949
NVAC	0.947
CRUS	0.947
TETC	0.947
XFIN	0.946
FOCS	0.944
JMAC	0.943
GENQ	0.941

10 Most Negative Correlations
NAKD	-0.955
AMGN	-0.935
THMA	-0.932
BHTG	-0.93
LGMK	-0.926
PCSA	-0.925
AHPI	-0.924
TRIT	-0.918
CREG	-0.911
PLIN	-0.907

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kalvista Pharmaceuticals Correlation - Currency/Commodity

0.13
( neutral )

0.54
( weak )

0.00
( neutral )

0.43
( neutral )

-0.22
( neutral )

-0.67
( moderate negative )

Kalvista Pharmaceuticals Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-802 000 (0.00 %)
EPS:	$-2.68

Q3	2024
Revenue:	$0
Gross Profit:	$-207 000 (0.00 %)
EPS:	$-0.840

Q2	2024
Revenue:	$0
Gross Profit:	$-197 000 (0.00 %)
EPS:	$-0.800

Q1	2024
Revenue:	$0
Gross Profit:	$-199 000 (0.00 %)
EPS:	$-0.740

Financial Reports:

No articles found.

Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.